Pfizer, Humedica ink real-world data pact

Share this article:
Geno Germano
Geno Germano

Pfizer continues to dive deeper into real-world data. In December the drugmaker and clinical data outfit Humedica jointly announced their intent to collaborate on studies examining the effectiveness of treatments.

The research will focus on the US for now, says a source, and will draw on Humedica's NorthStar data repository. NorthStar aggregates EHR data directly from providers, capturing medications, lab results and physician notes via natural-language processing, among other data points. (All information is de-identified, says Humedica.) The aim is to let pharma see how physicians are adopting brands.

Humedica will apply “Big Data solutions across the continuum of care,” said Michael Weintraub, Humedica's president and CEO, in the statement.

“The collaboration with Humedica will provide us with powerful information about healthcare delivery and patient outcomes,” added Geno Germano, president and general manager, Pfizer Specialty Care Business Unit.

The deal follows Pfizer's 2011 pact with Humana, also involving real-world data and comparative-effectiveness research, and underscores a desire among life science firms to harness Big Data to enhance outcomes.

Pacts to build up real-world data stores have been struck by AstraZeneca, which signed up with IMS Health and Wellpoint; Merck, who's working with online research platform PatientsLikeMe; and Sanofi, which teamed with Medco.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?